Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

Juno Therapeutics, Inc.. (2/29/16). "Press Release: Juno Therapeutics Reports Fourth Quarter and 2015 Financial Results". Seattle, WA.

Organisations Organisation Juno Therapeutics Inc. (Nasdaq: JUNO)
  Group Juno Therapeutics (Group)
  Organisation 2 Stage Cell Therapeutics GmbH
  Today Juno Therapeutics GmbH
  Group Juno Therapeutics (Group)
Product Product  JCAR017 (Juno Therapeutics)
  Index term 2 Stage Cell Therapeutics–Juno Therapeutics: investment, 201505 acquisition remaining 95% for €52.5m cash upfront + 486.3k shares + €135m milestones
Person Person Bishop, Hans E. (Juno Therapeutics 201601 CEO + Co-Founder before Dendreon + Bayer + GW + SKB)
     


   
Record changed: 2017-10-01

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for Juno Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px download




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px